Kyaw Aung

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial

Kyaw Aung, Sandra E. Fischer, Robert E. Denroche et al. · Clinical Cancer Research · 2017 · 636 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Patrick A. Ott, Yung‐Jue Bang, Dominique Berton-Rigaud et al. · Journal of Clinical Oncology · 2017 · 521 citations

Medicine, Oncology, Pharmacology +17

Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study

Janice M. Mehnert, Emily Bergsland, Bert H. O’Neil et al. · Cancer · 2020 · 150 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study

Janice M. Mehnert, Hope S. Rugo, Bert H. O’Neil et al. · Annals of Oncology · 2017 · 57 citations · Full text

Medicine, Oncology, Pharmacology +15

Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors.

Lillian L. Siu, Neeltje Steeghs, Tarek Meniawy et al. · Journal of Clinical Oncology · 2017 · 54 citations

Medicine, Oncology, Pharmacology +17